Fluidigm (NASDAQ:FLDM) issued its quarterly earnings data on Thursday. The medical research company reported ($0.20) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.12) by ($0.08), Bloomberg Earnings reports. Fluidigm had a negative net margin of 60.45% and a negative return on equity of 43.75%. The business had revenue of $28.20 million during the quarter, compared to analyst estimates of $30.16 million. Fluidigm’s revenue for the quarter was up 6.8% on a year-over-year basis. Fluidigm updated its Q3 2019 guidance to EPS.
Shares of Fluidigm stock traded down $4.10 during mid-day trading on Friday, hitting $8.05. 4,481,751 shares of the stock were exchanged, compared to its average volume of 600,747. Fluidigm has a twelve month low of $5.50 and a twelve month high of $14.90. The company has a market cap of $555.61 million, a PE ratio of -10.06 and a beta of 2.15. The stock has a 50-day moving average of $11.72. The company has a quick ratio of 2.86, a current ratio of 3.26 and a debt-to-equity ratio of 0.30.
In other Fluidigm news, Director Nicolas Barthelemy sold 5,100 shares of the firm’s stock in a transaction dated Monday, June 17th. The shares were sold at an average price of $12.43, for a total transaction of $63,393.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Levin Easterly Partners Llc sold 186,759 shares of the firm’s stock in a transaction dated Monday, July 1st. The stock was sold at an average price of $12.31, for a total transaction of $2,299,003.29. The disclosure for this sale can be found here. Insiders have sold a total of 1,152,660 shares of company stock worth $13,815,948 over the last ninety days. 2.20% of the stock is owned by corporate insiders.
Fluidigm Corporation creates, manufactures, and markets technologies and tools for life sciences research in the United States and Europe. It offers analytical systems comprising Helios, a CyTOF system, Hyperion imaging system, and Hyperion tissue imager; and assays and reagents, including Maxpar reagents and Maxpar human immune monitoring panel kit and workflow.
Further Reading: Cryptocurrencies
Receive News & Ratings for Fluidigm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fluidigm and related companies with MarketBeat.com's FREE daily email newsletter.